Latham & Watkins Advises Invetx in US$25.5 Million Series A Financing

A corporate team advised the veterinary therapeutics company in the funding round.

October 01, 2020

Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has raised an additional US$10.25 million in its Series A financing, bringing the total round size to US$25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics.

Latham & Watkins LLP represented Invetx in the transaction with a corporate team led by Boston/New York partner Kristen Grannis, with Boston associates Spencer Ricks, Peter Prial and Tyler Mills.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.